Quantcast

Latest UCB Stories

2011-06-09 11:16:00

ATLANTA, June 9, 2011 /PRNewswire/ -- UCB, Inc. today announced an agreement with the U.S. Department of Justice (DOJ) to resolve a previously disclosed government investigation into the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. As previously reported, the issues that were the subject of this investigation occurred more than six years ago, and as recognized by the DOJ, UCB has cooperated fully with the United States since learning of the...

2011-06-09 09:00:00

BRUSSELS, June 9, 2011 /PRNewswire/ -- A post hoc analysis from the RECOVER study (Randomized Evaluation of the 24-hour Coverage: Efficacy of Rotigotine Transdermal System) suggested that patients with Parkinson's disease who used Neupro® (rotigotine transdermal system) may experience improvements in key markers of mood/cognition, such as taking interest in surroundings and getting pleasure out of life. Additional data presented from a one year open label follow-up of...

2011-05-31 08:45:00

BALTIMORE, May 31, 2011 /PRNewswire/ -- UCB announced findings of the first cost-effectiveness analysis of Vimpat® (lacosamide) as add-on therapy for adults with uncontrolled partial-onset seizures. The findings were presented at the 16th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) annual meeting in Baltimore, MD, USA. Researchers used a simulated pharmaco-economic model to analyze standard anti-epileptic drug therapy with and without...

2011-05-10 09:00:00

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis (RA) patients treated with Cimzia® (certolizumab pegol), the only approved PEGylated anti-TNF, together with methotrexate (MTX), achieved a rapid response associated with improved long-term outcomes one year after treatment began. "These results are consistent...

2011-04-26 07:30:00

--Symposium Brings Together Industry, Investors, Scientific and Government Representatives to Advance Development of Drugs for Epilepsy-- MIDDLEBURG, Va., April 26, 2011 /PRNewswire-USNewswire/ -- The Epilepsy Therapy Project (ETP) today announced that a record number of emerging companies, industry executives, investors, scientific and government representatives will gather at the Antiepileptic Drug and Device Trials (AEDD) XI Conference to facilitate professional collaboration, funding...

2011-04-21 00:00:00

THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral density (BMD) for the treatment of postmenopausal osteoporosis (PMO). This Phase 2 study met its primary endpoint, demonstrating significant increases in lumbar spine bone mineral density at...

2011-04-14 06:00:00

BRUSSELS, April 14, 2011 /PRNewswire/ -- New 5-year data from the longest prospective open-label Restless Legs Syndrome (RLS) study to date, show that Neupro® (rotigotine) demonstrated continued symptomatic clinical benefit with a low risk of augmentation. Over the five year period, clinically significant augmentation occurred in 5.1% of patients receiving rotigotine at EU approved doses (1, 2 and 3 mg/24h) and in 13.2% of patients receiving one of the five evaluated...

2011-04-13 12:30:00

BRUSSELS, April 13, 2011 /PRNewswire/ -- New rotigotine data shown in four poster presentations at the 63rd Annual Meeting of the American Academy of Neurology (AAN) in Hawaii, U.S., highlighted the importance in Parkinson's disease (PD) of addressing both motor- and non-motor symptoms, such as sleep. The data also demonstrated the long-term efficacy and tolerability of rotigotine and showed that plasma rotigotine levels remained stable following patch removal and application of a new...

2011-02-08 01:00:00

BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL's patents known as the Queen et al. patents....

2011-01-12 11:15:00

ATLANTA, Jan. 12, 2011 /PRNewswire/ -- Comprehensive analyses of pooled data from three randomized, double-blind, placebo-controlled Phase II/III trials showing the efficacy and tolerability of Vimpat® (lacosamide) C-V for patients with partial-onset seizures, regardless of the type of concomitant AED used, have been published in the drug evaluation journal, CNS Drugs(1,2). Two key papers have reported that adjunctive lacosamide reduced seizures and improved responder...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related